Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
June 3, 2019 Cover
Volume 97, Issue 22
The cellular housecleaning and self-renewal process is implicated in neurodegenerative diseases, cancer, and more. Can biotech companies walk the fine line between boosting and inhibiting autophagy to treat disease without causing it?
Cover image:Autophagy, the process of cellular housecleaning and self-renewal, is implicated in neurodegenerative diseases, cancer, and more. Can biotech companies walk the fine line between boosting and inhibiting autophagy to treat disease without causing it?
Credit: Chris Gash
Autophagy: Drugging the yin and yang of the cell
The cellular housecleaning and self-renewal process is implicated in neurodegenerative diseases, cancer, and more. Can biotech companies walk the fine line between boosting and inhibiting autophagy to treat disease without causing it?
Hong Kong gives biotech a chance
After difficult years, new policies are helping a biotech sector bloom in the trading and banking hub
To get noble gases to forge bonds, chemists go to extremes
Despite challenging conditions and a lack of funding, some researchers still see rewards in coaxing reactivity from these nearly inert elements
-
From our archives: An essay on selenium, by Liu Tungsheng
To celebrate the International Year of the Periodic Table, C&EN is re-releasing its favorite essays from a special 2003 collectors’ issue celebrating the elements
-
US hemp boom creates chaos
Companies struggle with varying state laws, lack of federal guidance
-
Career Ladder: Anne Mallaband
This English chemist worked in industry before moving to academia and European science policy
ADVERTISEMENT
Science Concentrates
FDA approves second gene therapy, Zolgensma, to treat spinal muscular atrophy in infants
At $2,125,000, it is the most expensive drug in the world
